Arcus Biosciences, Inc. (RCUS) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | -156.3% | -142.9% |
| 2024 | 100.0% | -127.9% | -109.7% |
| 2023 | 100.0% | -290.6% | -262.4% |
| 2022 | 100.0% | -250.0% | -238.4% |
| 2021 | 100.0% | 14.1% | 13.8% |
Download Data
Export RCUS earnings history in CSV or JSON format
Free sign-in required to download data
Arcus Biosciences, Inc. (RCUS) Earnings Overview
As of March 2, 2026, Arcus Biosciences, Inc. (RCUS) reported trailing twelve-month net income of -$353M, reflecting -0.0% year-over-year growth. The company earned $-3.29 per diluted share over the past four quarters, with a net profit margin of -1.4%.
Looking at the long-term picture, RCUS's historical earnings data spans multiple years. The company achieved its highest annual net income of $53M in fiscal 2021.
Arcus Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including RVMD (-$1.13B net income), INCY ($1.29B net income, 0.3% margin), GMAB ($6.57B net income, 0.4% margin), RCUS has comparable earnings metrics. Compare RCUS vs RVMD →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$353M | -24.7% | -$386M | $-3.29 | -142.9% | -156.3% |
| 2024 | -$283M | +7.8% | -$330M | $-3.14 | -109.7% | -127.9% |
| 2023 | -$307M | -15.0% | -$340M | $-4.15 | -262.4% | -290.6% |
| 2022 | -$267M | -603.8% | -$280M | $-3.71 | -238.4% | -250.0% |
| 2021 | $53M | +143.1% | $54M | $0.71 | 13.8% | 14.1% |
| 2020 | -$123M | -45.2% | -$124M | $-2.13 | -157.7% | -159.0% |
| 2019 | -$85M | -70.8% | -$89M | $-1.73 | -564.7% | -591.4% |
| 2018 | -$50M | +6.6% | -$55M | $-1.43 | -593.7% | -656.8% |
| 2017 | -$53M | -195.4% | -$53M | $-2.16 | -3756.7% | -3782.1% |
| 2016 | -$18M | - | -$18M | $-0.73 | - | - |
See RCUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RCUS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RCUS vs AGIO
See how RCUS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RCUS growing earnings?
RCUS TTM EPS: $-3.29. Net income: $-353M. Earnings growth: -0.0%.
What are RCUS's profit margins?
Arcus Biosciences, Inc. net margin is -1.4%, with operating margin at -1.6%. Below-average margins reflect competitive or cost pressures.
How consistent are RCUS's earnings?
RCUS earnings data spans 2016-2025. The current earnings trend is -0.0% YoY. Historical data enables comparison across business cycles.